News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Maze Therapeutics, Inc. (MAZE) director Paula A. Johnson has filed an initial statement of beneficial ownership (Form 3), disclosing no holdings of MAZE shares or derivative positions. This filing establishes her reporting obligations as an insider but indicates no current transactions or existing ownership.
Sophie Kornowski, a new director at Maze Therapeutics, has filed a Form 3 indicating no beneficial ownership of the company's stock or derivatives. This filing merely establishes her status as an insider, with no reported transactions or holdings. The document confirms her role as …
Harold Bernstein, President, R&D & CMO at Maze Therapeutics, sold 16,142 shares of the company’s common stock for $445,620 on August 13, 2026. This transaction followed the exercise of stock options for the same number of shares at a lower price. The company's stock …
Walleye Capital LLC has acquired 128,006 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, a position valued at approximately $3.82 million. Despite this acquisition and a consensus "Buy" rating from analysts with an average price target of $66, the company reported a …
Wall Street Zen downgraded Maze Therapeutics (NASDAQ:MAZE) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $66.00. The company's shares opened at $27.18, representing a 1.8% decrease and significantly below its 52-week high …
Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 16,142 shares of company stock for $445,620 on August 13, 2026. This transaction followed an exercise of stock options at a lower price and was conducted under a Rule 10b5-1 trading plan. …
Truist Financial has reiterated its Buy rating for Maze Therapeutics (MAZE.US) and set a price target of $64. This indicates a strong belief in the company's future performance by the financial institution.
Maze Therapeutics' CMO, Harold Bernstein, sold 16,142 shares of company stock worth $445,680.62 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 50%. This follows a previous sale of 14,609 shares in July. Despite the insider selling and the company's ongoing unprofitability with …
Maze Therapeutics' President, R&D & CMO, Harold Bernstein, exercised 16,142 stock options and subsequently sold the resulting shares on August 13, 2026, under a Rule 10b5-1 trading plan. The options were exercised at $10.42 per share, and the common shares were sold at a …
Maze Therapeutics, Inc. has announced the appointments of Dr. Paula Johnson and Dr. Sophie Kornowski to its Board of Directors. Dr. Johnson brings extensive experience in cardiology and leadership from Wellesley College and Johnson & Johnson, while Dr. Kornowski contributes over 35 years of …
Maze Therapeutics, a clinical-stage biopharmaceutical company, has appointed Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. These appointments bring extensive clinical, research, and biopharmaceutical leadership experience to the company. Maze Therapeutics is advancing its pipeline of small molecule …
BTIG Research has reaffirmed its "Buy" rating for Maze Therapeutics (NASDAQ:MAZE), setting a $46 price target, indicating a potential 68.44% upside. The company has a consensus "Buy" rating from analysts with an average target price of $66, despite some insider selling totaling approximately $3.9 …
Maze Therapeutics (NASDAQ:MAZE) has received an average "Buy" rating from eleven brokerages, with an average 12-month price target of $66.00, significantly higher than its current trading price of $27.31. The company recently reported quarterly earnings per share of -$0.76, meeting estimates, while analysts anticipate …
Maze Therapeutics announced its financial results for the second quarter of 2026 and provided updates on recent pipeline progress. The company highlighted advancements in its genetic modifier programs, focusing on their lead candidates and ongoing research efforts. Financial details were also provided, outlining the …
Maze Therapeutics reported a Q2 net loss of $44.7 million, missing analyst EPS estimates, but significantly boosted its cash reserves to $494.9 million, extending its operational runway to 2029. The company saw increased R&D and G&A expenses while advancing its key programs, MZE829 and …
Maze Therapeutics reported its second-quarter 2026 financial results, highlighting ongoing clinical trials and a strong financial position. The company's Phase 2 HORIZON trial for MZE829 in AMKD is on track with updated data expected in late 2026 or early 2027, and the Phase 2 …
Maze Therapeutics, Inc. CEO Jason V. Coloma indirectly sold a total of 34,501 shares of common stock on August 3, 2026, through The Coloma 2021 Irrevocable Trust and the Coloma Family Trust. These sales, executed via a Rule 10b5-1 trading plan adopted in February …
The article reports on a Form 144 filing by Maze Therapeutics for August 3rd. It is a brief news item from Investing.com, likely indicating an insider transaction or an intent to sell restricted stock by the company. The content also includes market data, other …
MAZE (NASDAQ: MAZE) has filed a Form 144 detailing proposed sales of its common stock, including 34,501 shares valued at over $922,000 through UBS Financial Services. The filing also reveals past transactions, specifically gifts from Jason Coloma in 2021, and recent open-market sales by …
Janus Henderson Group PLC reduced its stake in Maze Therapeutics (NASDAQ:MAZE) by 9.0% in the first quarter, selling over 283,000 shares but still retaining a significant holding worth $85.3 million. The company's stock opened down 2.6% at $26.92, and it recently reported a quarterly …
This article analyzes the valuation of Maze Therapeutics Inc (MAZE), categorizing its current forward PS ratio as "Fair" compared to its five-year average. It provides a fair price range for MAZE between $11.77 and $125.45 based on a relative valuation method. The analysis also …
Atul Dandekar, an officer at Maze Therapeutics (MAZE), reported exercising 7,500 stock options at $10.42 per share and subsequently selling 7,500 common shares in multiple transactions at weighted-average prices of $27.3064 and $27.89. These transactions, which generated an approximate pre-tax spread of $127,000, were …
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company with a market capitalization of $1.53 billion, focusing on precision medicines for kidney and metabolic diseases. Analysts project a significant potential upside of 126.37%, with an average target price of $62.55, driven by an innovative …
BlackRock, Inc. has disclosed a passive beneficial ownership of 5.4% in Maze Therapeutics Inc. common stock, amounting to 2,978,114 shares. The firm has sole voting power over 2,922,889 shares and sole dispositive power over all 2,978,114 shares, with no shared powers. This information was …
Atul Dandekar, a shareholder of Maze Therapeutics, Inc. (NASDAQ: MAZE), has filed to sell up to 22,500 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. This planned transaction, with an anticipated date of July 29, 2026, follows an exercise …
Search by ticker symbol or company name and select a result to open its chart.